We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Sanofi-Synthelabo, a member of the sanofi-aventis Group, has announced results
of a randomized, double-blind, placebo-controlled trial evaluating the safety
and efficacy of Hyalgan versus saline, in the treatment of osteoarthritis
(OA) of the ankle.
DOV Pharmaceutical, a leader in triple reuptake inhibitor drug discovery and
development, has initiated the first Phase I clinical trial with DOV 102,677,
believed to be a potent inhibitor of serotonin, norepinephrine and dopamine
reuptake, with preferential action on the dopamine transporter protein.
Genzyme has announced that the first patient has been treated in a Phase II
clinical trial examining the safety and effectiveness of locally delivered gene
transfer for patients with peripheral arterial disease.
American Pharmaceutical Partners has announced that the pivotal Phase III clinical
study of Abraxane for injectable suspension in patients with metastatic breast
cancer demonstrated a statistically significant improvement in survival in second-line
patients.
Join FDAnews Monday, Feb. 28, to hear former FDA official Martin Browning
provide insights on "Preparing for Systems-Based Inspections" in a
90-minute, interactive audioconference. You'll get briefed on what's coming
from the FDA and learn how to adjust your systems and SOPs before inspectors
arrive.
Nymox Pharmaceutical has been issued U.S. patents for a method of measuring
cholesterol levels using saliva and for novel Alzheimer's disease drug candidates
targeting spherons.
The U.S. Patent and Trademark Office has granted a five-year patent-term extension
to United Therapeutics for its pulmonary hypertension drug Remodulin.
Perlegen Sciences has been awarded a grant from the National Cancer Institute
to study tumor-specific DNA mutations involved in colorectal cancer in collaboration
with the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.